Interleukin 3 News and Research

RSS

New genetic risk factor for coeliac disease

An international research consortium investigating the genetic causes of intestinal inflammatory conditions has identified a new genetic risk factor for coeliac disease.

14 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Brain inflammation may actually be a friend for Alzheimer's patients

Inflammation in the brain may not be so bad after all when it comes to Alzheimer's disease.

3 Jun 2007

Blood test may help signal tumor's remission, return in throat cancer patients

A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research .

3 Jun 2007

Green tea may help prevent bone destruction in arthritis

In rheumatoid arthritis, a person's own immune system attacks the joints by activating the synovial tissue that lines the body's movable joints, causing inflammation, swelling, pain and eventually erosion of the bone and cartilage and deformation of the joint.

30 Apr 2007

Green tea may soothe pain of rheumatoid arthritis

According to the latest research a compound in green tea may provide therapeutic benefits to people with rheumatoid arthritis.

30 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007

We need to balance out our intake of omega-6 and omega-3 fatty acids

A new study suggests that people whose diets contain dramatically more of one kind of polyunsaturated fatty acid than another may be at greater risk for both clinical depression and certain inflammatory diseases.

3 Apr 2007

Body uses a 'dual key' system to secure immune system

"Dual key" activation, in which two people must act in concert to launch a weapon, is often installed to safeguard highly destructive arms.

2 Apr 2007

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

The addition of immunotherapy to chemotherapy for malignant skin cancer that has spread does not improve survival rates, researchers have found, and patients have more serious side effects, such as anemia, when the two treatments are combined.

1 Mar 2007

Vaccine against group B Streptococci

The search for a vaccine against group B streptococci Group B streptococci are one of the leading causes of infection in newborn infants, causing pneumonia, septicaemia or meningitis.

12 Feb 2007

High-dose progesterone treatment helps at-risk pregnant women avoid premature delivery

In this study, 45 women who experienced premature labor (before 37 weeks gestation) were randomly divided into treatment and observation groups. The treatment group received twice-weekly 341-mg doses of progesterone until week 36.

11 Feb 2007

Gums produce substances that lead to degeneration of the jawbone

Our gums' own cells produce the substances that lead to the degeneration of the jawbone. This is one of the findings in a dissertation that Py Palmqvist defended at Umea University in Sweden recently.

24 Jan 2007

Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme

Glioblastoma multiforme is among the most aggressive and difficult cancers to treat. Now, researchers at Penn State University have shown that a lipid-based nanoparticle, designed to bind to a specific receptor found on malignant brain cells but not healthy ones, improves the potency of a common anticancer drug and slows significantly the growth of glioblastoma in mice.

8 Jan 2007